Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES CorpOSOK · Entity 7808 | Chief Development Officer | July 20, 2017 | July 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date July 20, 2017 · Filed July 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,453 |
Reported balance
After 2017-07-20 transaction · row 1
1 source rowRow 1 · 2017-07-20 · Grant · Acquired 215,453 · Balance 215,453 F1: The reporting person acquired the shares of NeuroOne Medical Technologies Corporation ("NMTC") on July 20, 2017, in exchange for shares of the common stock of NeuroOne, Inc. ("NeuroOne"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of July 20, 2017, between NMTC, OSOK Acquisition Company and NeuroOne, pursuant to which NeuroOne became a wholly-owned subsidiary of NMTC. Per the terms of the Merger Agreement, each share of NeuroOne common stock was converted into the right to receive 17.0103706 shares of NMTC common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person acquired the shares of NeuroOne Medical Technologies Corporation ("NMTC") on July 20, 2017, in exchange for shares of the common stock of NeuroOne, Inc. ("NeuroOne"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of July 20, 2017, between NMTC, OSOK Acquisition Company and NeuroOne, pursuant to which NeuroOne became a wholly-owned subsidiary of NMTC. Per the terms of the Merger Agreement, each share of NeuroOne common stock was converted into the right to receive 17.0103706 shares of NMTC common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2017 Filed Jul 24, 2017 19:52 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp OSOK · Entity 7808 | GrantCommon Stock | 215,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-17-000062 · primary_doc.xml · nonDerivative · entry 1 Bachinski Thomas · CIK 0001710364 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,453 F1 · price: The reporting person acquired the shares of NeuroOne Medical Technologies Corporation ("NMTC") on July 20, 2017, in exchange for shares of the common stock of NeuroOne, Inc. ("NeuroOne"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of July 20, 2017, between NMTC, OSOK Acquisition Company and NeuroOne, pursuant to which NeuroOne became a wholly-owned subsidiary of NMTC. Per the terms of the Merger Agreement, each share of NeuroOne common stock was converted into the right to receive 17.0103706 shares of NMTC common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.